Borrelia burgdorferi

Abell Pest Control Sheds Light on Tick Surge

Retrieved on: 
Monday, March 11, 2024

Due to global warming, the recent abnormally warm winter has allowed ticks to move to new areas and lengthen their active season,” explained Aaron Soudant, Director of Quality Assurance at Abell Pest Control.

Key Points: 
  • Due to global warming, the recent abnormally warm winter has allowed ticks to move to new areas and lengthen their active season,” explained Aaron Soudant, Director of Quality Assurance at Abell Pest Control.
  • Abell Pest Control offers the following tips to avoid tick bites and minimize the risk of Lyme disease:
    Dress Appropriately: Wear long pants, and long sleeves and opt for light-colored clothing to make ticks easier to spot.
  • Abell Pest Control, a leader in pest control solutions, is dedicated to raising awareness about tick-borne illnesses and empowering communities with knowledge and resources for protection.
  • Celebrating 100 years of trust, Abell Pest Control has been safeguarding homes and businesses since 1924.

Preclinical Data on PIV5-based Intranasal Vaccine Against Lyme Disease Demonstrates Durable Immune Response

Retrieved on: 
Thursday, February 15, 2024

“This peer-reviewed research on a vaccine candidate against Lyme disease demonstrates the ability of the PIV5 platform to stimulate durable immune responses against a vector-borne pathogen, broadening its utility.

Key Points: 
  • “This peer-reviewed research on a vaccine candidate against Lyme disease demonstrates the ability of the PIV5 platform to stimulate durable immune responses against a vector-borne pathogen, broadening its utility.
  • It is the most prevalent vector-borne disease in the US and Europe, yet there is no licensed vaccine available.
  • In the article entitled “Intranasal vaccine for Lyme disease provides protection against tick transmitted Borrelia burgdorferi beyond one year,” a two-dose course of the PIV5-based intranasal Lyme vaccine was shown to provide superior protection against challenge with ticks carrying up to 19 different B. burgdorferi strains, when compared against a subcutaneous Lyme vaccine control (purified recombinant OspAB31 in alum adjuvant).
  • “These preclinical data showing long lasting protection against infection after a prime-boost immunization are extremely encouraging.”

U.S. Department of Health and Human Services and Steven and Alexandra Cohen Foundation Name T2 Biosystems a Phase 2 Winner in the LymeX Diagnostics Prize

Retrieved on: 
Wednesday, February 7, 2024

As a Phase 2 winner, T2 Biosystems will receive $265,000.

Key Points: 
  • As a Phase 2 winner, T2 Biosystems will receive $265,000.
  • The T2Lyme Panel is intended to test individuals with signs and symptoms of Lyme disease and aid in the diagnosis of early Lyme disease.
  • “We are thrilled to announce that we have been selected as a Phase 2 winner in the LymeX Diagnostics Prize,” stated John Sperzel, Chairman and CEO of T2Biosystems.
  • Thanks to a $10 million pledge to the LymeX Diagnostics Prize from the Steven & Alexandra Cohen Foundation, at least $7 million in additional LymeX prizes are projected to be available in proposed future phases.

Combination Antibiotic Therapies May Be Capable of Eradicating Lyme Disease, According to Investigational Study Funded by Bay Area Lyme Foundation

Retrieved on: 
Tuesday, November 21, 2023

These combination therapies were able to eradicate the bacteria from tissue samples, and the study was conducted by Bay Area Lyme Foundation Scientific Advisory Board member Monica Embers Ph.D. , along with other researchers from Tulane University.

Key Points: 
  • These combination therapies were able to eradicate the bacteria from tissue samples, and the study was conducted by Bay Area Lyme Foundation Scientific Advisory Board member Monica Embers Ph.D. , along with other researchers from Tulane University.
  • While none of the single courses of antibiotics eliminated persistent infection in this investigational study, some combinations of already FDA-approved antimicrobial treatments were able to eradicate the bacteria.
  • Previous studies funded by Bay Area Lyme Foundation also found other compounds, including natural botanicals, to show promise in killing Borrelia burgdorferi and superiority over commonly prescribed antibiotics in laboratory research.
  • This study was made possible by Bay Area Lyme Foundation’s science research grant program, which includes support from Project Lyme .

Research Funded by Bay Area Lyme Foundation Identifies New Investigational Therapy Regimen Capable of Irreversibly Damaging Lyme Bacteria in Laboratory Tests

Retrieved on: 
Wednesday, November 1, 2023

“Bay Area Lyme concentrates on funding innovative research, including projects where knowledge can be deployed from other areas of medicine.

Key Points: 
  • “Bay Area Lyme concentrates on funding innovative research, including projects where knowledge can be deployed from other areas of medicine.
  • He encouraged scientists to take cancer staging techniques and immunotherapy learnings from oncology and apply them to Lyme research.
  • Bay Area Lyme Foundation also funded University of North Carolina collaborator, Matt Redinbo , PhD’s research on HS-291; his lab’s crystallography work was instrumental in the discovery process.
  • Bay Area Lyme Foundation’s research grant program was made possible by the support from the Fairbairn Family, the Younger Family Fund, and Project Lyme .

Bay Area Lyme Foundation ELA Winner Uses Metabolic Modeling to Predict 77 Unique Drug Targets in Lyme Disease Bacterium

Retrieved on: 
Thursday, October 19, 2023

PORTOLA VALLEY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation , a leading sponsor of Lyme disease research in the US, today announced the findings of a study identifying new essential gene and enzyme drug targets in Lyme disease bacterium, which resulted, in-part, from a grant provided to Peter Gwynne, one of Bay Area Lyme Foundation’s 2022 Emerging Leader Award (ELA) winners.

Key Points: 
  • PORTOLA VALLEY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation , a leading sponsor of Lyme disease research in the US, today announced the findings of a study identifying new essential gene and enzyme drug targets in Lyme disease bacterium, which resulted, in-part, from a grant provided to Peter Gwynne, one of Bay Area Lyme Foundation’s 2022 Emerging Leader Award (ELA) winners.
  • Published in the peer-reviewed journal mSystems, the study uses the most comprehensive metabolic modeling to date to predict 77 unique drug targets in Borrelia burgdorferi, the bacterium that causes Lyme disease — a condition affecting nearly 500,000 new patients annually.
  • “Lyme disease is often treated using long courses of antibiotics, which can cause side effects for patients and risks the evolution of antimicrobial resistance.
  • “There is a desperate need for therapeutics that can more effectively and precisely treat Lyme disease,” said Linda Giampa, executive director of the Bay Area Lyme Foundation.

USDA Approves Novel Vaccine Against Wildlife Spread of the Bacterium Responsible for Lyme Disease

Retrieved on: 
Tuesday, May 9, 2023

MEMPHIS, Tenn., May 9, 2023 /PRNewswire/ -- US Biologic, Inc. , a leading global entity in the development, commercialization, and distribution of orally delivered vaccines, announces USDA Conditional Licensure of its novel oral vaccine against the wildlife spread of Borrelia burgdorferi, the bacterium responsible for Lyme disease, the number one vector-borne disease in the U.S.

Key Points: 
  • MEMPHIS, Tenn., May 9, 2023 /PRNewswire/ -- US Biologic, Inc. , a leading global entity in the development, commercialization, and distribution of orally delivered vaccines, announces USDA Conditional Licensure of its novel oral vaccine against the wildlife spread of Borrelia burgdorferi, the bacterium responsible for Lyme disease, the number one vector-borne disease in the U.S.
  • The only known vector is the blacklegged tick, which is infected primarily by feeding on small wildlife mammals, particularly white-footed mice.
  • The vaccine, called "Borrelia Burgdorferi Bacterin," is spray-coated onto pellets that the mice consume.
  • "Our team members, our leadership, and our partners are dedicated to disease prevention," says US Biologic Chief Executive Officer Mason Kauffman.

T2 Biosystems Advances to the Phase 2 in HHS and the Steven and Alexandra Cohen Foundation’s LymeX Diagnostics Prize

Retrieved on: 
Monday, February 6, 2023

The goal of the multiphase LymeX Innovation Accelerator (LymeX) prize competition is to nurture the development of diagnostics toward Food and Drug Administration (FDA) review.

Key Points: 
  • The goal of the multiphase LymeX Innovation Accelerator (LymeX) prize competition is to nurture the development of diagnostics toward Food and Drug Administration (FDA) review.
  • Based on the judges’ evaluations, the panel will recommend up to five Phase 2 winners of the LymeX Diagnostics Prize.
  • Thanks to a $10 million pledge to the LymeX Diagnostics Prize from the Steven & Alexandra Cohen Foundation, $9 million in LymeX prizes are projected to be available in proposed future phases.
  • Phase 2 is part of this multi-year, multi-phased LymeX Diagnostics Prize series that HHS plans to announce further details for in early 2023.

Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease

Retrieved on: 
Thursday, December 15, 2022

IRVINE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced positive topline results from the completed Phase 1b Callisto trial and the enrollment of the first subject in the Carpo Phase 2a trial. The Callisto and Carpo trials are designed to evaluate TP-05, a novel investigative oral therapeutic for the potential prevention of Lyme disease.

Key Points: 
  • The Callisto and Carpo trials are designed to evaluate TP-05, a novel investigative oral therapeutic for the potential prevention of Lyme disease.
  • Additionally, exploratory ex-vivo tick kill modeling utilizing serum from TP-05-treated subjects demonstrated potent, rapid killing of adult and nymph ticks.
  • Tarsus also announced the enrollment of the first patient in the Carpo trial, evaluating TP-05 for the potential prevention of Lyme disease in humans.
  • TP-05 is believed to be the only non-vaccine, drug-based, preventative therapeutic in development designed to kill ticks to potentially prevent Lyme disease transmission.

HHS and the Cohen Foundation Name T2 Biosystems a Phase 1 Winner in LymeX Diagnostics Prize

Retrieved on: 
Monday, November 7, 2022

LEXINGTON, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the U.S. Department of Health and Human Services (HHS) and the Steven & Alexandra Cohen Foundation (Cohen Foundation) have selected T2 Biosystems as a Phase 1 winner in the LymeX Diagnostics Prize, a LymeX Innovation Accelerator (LymeX) prize competition to accelerate the development of Lyme disease diagnostics.

Key Points: 
  • LEXINGTON, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the U.S. Department of Health and Human Services (HHS) and the Steven & Alexandra Cohen Foundation (Cohen Foundation) have selected T2 Biosystems as a Phase 1 winner in the LymeX Diagnostics Prize, a LymeX Innovation Accelerator (LymeX) prize competition to accelerate the development of Lyme disease diagnostics.
  • As a Phase 1 winner, T2 Biosystems will receive $100,000 and an invitation to participate in a second phase.
  • At the discretion of HHS and the Cohen Foundation, and subject to availability of future funding, at least one additional phase may follow Phase 2.
  • Thanks to a $10 million pledge to the LymeX Diagnostics Prize from the Cohen Foundation, $9 million in additional LymeX prizes are projected to be available in proposed future phases.